Q3 2023 · 13F-HR
Vivo Capital, LLCholdings as filed
Filed 2023-11-08 · accession 0001213900-23-084732
$912.8M
Reported value
53
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 37186H100 | — | Genetron Holdings Ltd | $104.6M | 11.5% | 8,124,174 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $94.5M | 10.4% | 3,203,093 | Common | SOLE |
| 413197104 | HRMY | Harmony Biosciences Holdings Inc | $85.4M | 9.36% | 2,606,247 | Common | SOLE |
| 925050106 | VRNA | Verona Pharma PLC | $69.3M | 7.59% | 4,249,918 | Common | SOLE |
| 05337M104 | — | Avadel Pharmaceuticals PLC | $42.2M | 4.62% | 4,096,428 | Common | SOLE |
| 87650L103 | TARS | Tarsus Pharmaceuticals Inc | $40.2M | 4.40% | 2,262,200 | Common | SOLE |
| P8696W104 | SVA | Sinovac Biotech Ltd. | $38.2M | 4.18% | 5,900,000 | Common | SOLE |
| 374163103 | GERN | Geron Corp | $35.0M | 3.84% | 16,524,634 | Common | SOLE |
| 880881107 | 430 | Terns Pharmaceuticals Inc | $33.5M | 3.67% | 6,657,992 | Common | SOLE |
| 38406L103 | — | Gracell Biotechnologies Inc | $31.3M | 3.43% | 10,881,144 | Common | SOLE |
| 92790C104 | VRDN | Viridian Therapeutics Inc | $25.7M | 2.82% | 1,678,207 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals Inc | $23.1M | 2.54% | 1,873,704 | Common | SOLE |
| 19240Q201 | COGT | Cogent Biosciences Inc | $21.9M | 2.40% | 2,244,941 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc | $20.3M | 2.22% | 4,220,048 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx Inc. | $18.1M | 1.98% | 503,565 | Common | SOLE |
| 92332V107 | VTYXUSD | Ventyx Biosciences Inc | $14.7M | 1.61% | 422,075 | Common | SOLE |
| 75525N107 | — | Rayzebio Inc | $14.1M | 1.54% | 633,576 | Common | SOLE |
| 45114M109 | — | Icosavax, Inc. | $13.2M | 1.45% | 1,704,568 | Common | SOLE |
| 04635X102 | CATBUSD | Astria Therapeutics Inc | $12.5M | 1.37% | 1,681,199 | Common | SOLE |
| 92337C203 | VSTM | Verastem Inc | $12.5M | 1.37% | 1,538,461 | Common | SOLE |
| 20451W101 | CMPS | Compass Pathway PLC | $11.9M | 1.30% | 1,608,000 | Common | SOLE |
| 98887Q104 | ZLAB | Zai Lab Ltd ADR | $11.1M | 1.21% | 454,606 | Common | SOLE |
| 02083G100 | NVLSEUR | Alpine Immune Sciences Inc | $10.5M | 1.15% | 914,913 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc | $10.4M | 1.14% | 350,000 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics Inc | $9.3M | 1.02% | 1,035,136 | Common | SOLE |
| 449778109 | IOBTQ | IO Biotech Inc | $8.7M | 0.95% | 6,173,439 | Common | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $8.5M | 0.93% | 400,000 | Common | SOLE |
| 483497103 | KALV | KalVista Pharmaceuticals Inc. | $8.2M | 0.90% | 856,008 | Common | SOLE |
| 24661P807 | DCTH | Delcath Systems, Inc. | $7.5M | 0.82% | 1,855,191 | Common | SOLE |
| 805111101 | SVRA | Savara Inc | $7.2M | 0.79% | 1,913,349 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics Inc | $7.0M | 0.77% | 3,556,023 | Common | SOLE |
| 01671P100 | ALLKGUSD | Allakos Inc | $6.8M | 0.74% | 2,988,000 | Common | SOLE |
| 00032Q104 | WHWK | Aadi Bioscience Inc | $6.5M | 0.71% | 509,572 | Common | SOLE |
| 00461U105 | ACRS | Aclaris Therapeutics, Inc. | $6.2M | 0.67% | 898,631 | Common | SOLE |
| 45783C101 | — | Instil Bio Inc | $5.3M | 0.59% | 12,486,787 | Common | SOLE |
| 68622P109 | ORIC | Oric Pharmaceuticals Inc | $4.7M | 0.52% | 777,944 | Common | SOLE |
| 097702104 | BOLT1EUR | Bolt Therapeutics Inc | $4.0M | 0.44% | 3,871,291 | Common | SOLE |
| 04280A100 | ARWR | Arrowhead Pharmaceuticals Inc | $3.7M | 0.40% | 137,411 | Common | SOLE |
| 23306J101 | — | DBV Technologies SA | $3.7M | 0.40% | 2,708,875 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics Inc | $3.5M | 0.38% | 1,856,011 | Common | SOLE |
| 90466Y103 | — | Unicycive Therapeutics | $3.0M | 0.33% | 3,470,152 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $3.0M | 0.33% | 655,057 | Common | SOLE |
| 01626L105 | — | Aligos Therapeutics Inc | $2.6M | 0.29% | 3,547,030 | Common | SOLE |
| 359616109 | FULC | Fulcrum Therapeutics Inc | $2.3M | 0.25% | 520,000 | Common | SOLE |
| 185634102 | CLNNEUR | Clene Inc | $1.4M | 0.15% | 2,645,338 | Common | SOLE |
| 45258K109 | — | Impel NeuroPharma Inc | $1.2M | 0.14% | 2,884,789 | Common | SOLE |
| 04522R101 | — | Aslan Pharmaceuticals Ltd | $1.1M | 0.12% | 568,182 | Common | SOLE |
| 09077B104 | BCABGBP | BioAtla Inc | $908,108 | 0.10% | 534,181 | Common | SOLE |
| 192005106 | CDXS | Codexis, Inc | $733,592 | 0.08% | 388,144 | Common | SOLE |
| 76200L309 | RZLT | Rezolute Inc | $639,459 | 0.07% | 484,439 | Common | SOLE |
| 03236M200 | — | Amyris, Inc | $465,050 | 0.05% | 7,750,828 | Common | SOLE |
| 438083107 | FIXXEUR | Homology Medicines, Inc. | $432,980 | 0.05% | 370,068 | Common | SOLE |
| 74019P108 | — | Precision Biosciences Inc | $47,869 | 0.01% | 140,255 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.